• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $KPTI

    Karyopharm Therapeutics Inc.

    Subscribe to $KPTI
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. The company's lead compound, XPOVIO (selinexor), is approved in the U.S. in various hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. Its NEXPOVIO (selinexor) has also been granted conditional marketing authorization in combination with dexamethasone for adult patients with heavily pretreated multiple myeloma by the European Commission. In addition, the company's SINE compounds also show biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Further, it also has various investigational programs in clinical or preclinical development. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

    IPO Year: 2013

    Exchange: NASDAQ

    Website: karyopharm.com

    Peers

    $KZR

    Recent Analyst Ratings for Karyopharm Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    1/19/2023$8.00Overweight
    Piper Sandler
    11/4/2022$7.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    3/8/2022$12.00 → $8.00Sector Perform
    RBC Capital
    3/2/2022$8.00 → $6.00Market Perform
    SVB Leerink
    2/9/2022$8.00Underweight → Neutral
    JP Morgan
    1/10/2022$6.00 → $8.00Market Perform
    SVB Leerink
    12/9/2021$8.00 → $9.00Sector Perform
    RBC Capital
    11/19/2021$27.00 → $10.00Overweight → Equal-Weight
    Morgan Stanley
    10/12/2021$29.00 → $27.00Overweight
    Morgan Stanley
    8/6/2021Overweight → Neutral
    JP Morgan
    See more ratings

    Karyopharm Therapeutics Inc. SEC Filings

    See more
    • SEC Form DEFA14A filed by Karyopharm Therapeutics Inc.

      DEFA14A - Karyopharm Therapeutics Inc. (0001503802) (Filer)

      4/14/25 8:19:11 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Karyopharm Therapeutics Inc.

      DEF 14A - Karyopharm Therapeutics Inc. (0001503802) (Filer)

      4/14/25 8:15:19 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Therapeutics Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - Karyopharm Therapeutics Inc. (0001503802) (Filer)

      2/24/25 4:16:55 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Karyopharm Therapeutics Inc.

      10-K - Karyopharm Therapeutics Inc. (0001503802) (Filer)

      2/19/25 7:36:40 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Karyopharm Therapeutics Inc. (0001503802) (Filer)

      2/19/25 7:32:17 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Karyopharm Therapeutics Inc.

      8-K - Karyopharm Therapeutics Inc. (0001503802) (Filer)

      1/31/25 4:05:27 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Karyopharm Therapeutics Inc.

      8-K - Karyopharm Therapeutics Inc. (0001503802) (Filer)

      1/30/25 4:06:06 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Karyopharm Therapeutics Inc. (0001503802) (Filer)

      1/13/25 8:34:48 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Karyopharm Therapeutics Inc. (0001503802) (Filer)

      1/2/25 7:08:18 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Karyopharm Therapeutics Inc.

      DEF 14A - Karyopharm Therapeutics Inc. (0001503802) (Filer)

      12/16/24 4:00:03 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Karyopharm Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

      -- Conference Call Scheduled for Monday, May 12, 2025, at 4:30 p.m. ET -- NEWTON, Mass., May 8, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report first quarter 2025 financial results on Monday, May 12, 2025. Karyopharm's management team will host a conference call and audio webcast at 4:30 p.m. ET on Monday, May 12, 2025, to discuss the financial results and other company updates. To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeu

      5/8/25 4:05:00 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      NEWTON, Mass., May 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 983 restricted stock units (RSUs) to two newly-hired employees. These RSU awards were granted as of April 30, 2025 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4). Each RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecut

      5/1/25 4:05:00 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      NEWTON, Mass., April 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 1,850 restricted stock units (RSUs) to two newly-hired employees. These RSU awards were granted as of March 31, 2025 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4). Each RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three cons

      4/1/25 4:05:00 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      NEWTON, Mass., March 3, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 3,316 restricted stock units (RSUs) to five newly-hired employees. These RSU awards were granted as of February 28, 2025 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4). Each RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three

      3/3/25 4:05:00 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Announces 1-for-15 Reverse Stock Split

      NEWTON, Mass., Feb. 24, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will implement a 1-for-15 reverse stock split of the issued shares of the Company's common stock ("Reverse Stock Split"), effective at 5:00 p.m. Eastern Time on February 25, 2025. The Reverse Stock Split was approved by the Company's stockholders at the Company's Special Meeting of Stockholders held on January 30, 2025, with the final ratio subsequently determined by the Company's Board of Directors. One of the primary goals of the Reverse Stock Split is to increase the per-share market price of the Compa

      2/24/25 8:40:00 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress

      – Total Revenue of $145 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $113 Million for Full Year 2024 – – Top-Line Data Readout from Phase 3 SENTRY Trial Evaluating Selinexor in Combination with Ruxolitinib in Patients with JAKi-Naïve Myelofibrosis Anticipated in 2H 2025; Company on Track to Complete Enrollment in 1H 2025 – – Company Announces Update to Phase 3 XPORT-EC-042 Trial of Selinexor as Maintenance Therapy in Advanced or Recurrent TP53 Wild-Type Endometrial Cancer. Following Dialogue with the FDA Regarding the Evolving Treatment Landscape, Trial to Focus Enrollment on Patients with Either pMMR Tumors or Patients with dMMR Tumors that are Medically Ineligible for Checkp

      2/19/25 7:30:00 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

      -- Conference Call Scheduled for Wednesday, February 19, 2025, at 8:00 a.m. ET -- NEWTON, Mass., Feb. 12, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report fourth quarter and full year 2024 financial results on Wednesday, February 19, 2025. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Wednesday, February 19, 2025, to discuss the financial results and other company updates. To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask

      2/12/25 7:00:00 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      NEWTON, Mass., Feb. 3, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 28,000 restricted stock units (RSUs) to three newly-hired employees. These RSU awards were granted as of January 31, 2025 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4). Each RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three

      2/3/25 4:05:00 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives

      – Opportunity to Define a New Myelofibrosis Treatment Paradigm with Top-Line Data Readout from Phase 3 SENTRY Trial Evaluating Selinexor in Combination with Ruxolitinib in Patients with JAKi-Naïve Myelofibrosis Anticipated in 2H 2025; Company On Track to Complete Enrollment in 1H 2025 –  – Recently Announced Key Leadership Changes, including the Appointment of Lori Macomber as Chief Financial Officer and Brendan Strong as SVP of Investor Relations and Corporate Communications –  – Preliminary Unaudited Full Year 2024 Total Revenue and U.S. XPOVIO® (selinexor) Net Product Revenue Expected to be Approximately $145 Million and $113 Million, Respectively – NEWTON, Mass., Jan. 13, 2025 /PRNewswi

      1/13/25 8:30:00 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      NEWTON, Mass., Jan. 2, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted a stock option to purchase an aggregate of 101,250 shares of Karyopharm's common stock and an aggregate of 108,540 restricted stock units (RSUs) to four newly-hired employees. These RSU awards were granted as of December 31, 2024 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option has an exercise

      1/2/25 4:05:00 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Karyopharm Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    Karyopharm Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • President and CEO Paulson Richard A. sold $1,680 worth of shares (236 units at $7.12), decreasing direct ownership by 0.29% to 82,503 units (SEC Form 4)

      4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)

      5/7/25 5:03:41 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP & Chief Medical Officer Rangwala Reshma sold $2,585 worth of shares (419 units at $6.17), decreasing direct ownership by 1% to 28,853 units (SEC Form 4)

      4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)

      4/24/25 4:40:51 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Paulson Richard A. sold $916 worth of shares (245 units at $3.74), decreasing direct ownership by 0.30% to 82,739 units (SEC Form 4)

      4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)

      4/7/25 4:59:22 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP & Chief Medical Officer Rangwala Reshma sold $22,562 worth of shares (3,587 units at $6.29), decreasing direct ownership by 11% to 29,272 units (SEC Form 4)

      4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)

      3/6/25 4:26:15 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Paulson Richard A. sold $73,555 worth of shares (11,694 units at $6.29), decreasing direct ownership by 12% to 82,984 units (SEC Form 4)

      4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)

      3/6/25 4:27:06 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP & Chief Commercial Officer Cheng Sohanya Roshan sold $21,669 worth of shares (3,445 units at $6.29), decreasing direct ownership by 9% to 34,314 units (SEC Form 4)

      4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)

      3/6/25 4:27:58 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Chief Development Officer Poulton Stuart sold $22,317 worth of shares (3,548 units at $6.29), decreasing direct ownership by 11% to 27,414 units (SEC Form 4)

      4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)

      3/6/25 4:24:37 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Accounting Officer Abate Kristin sold $3,592 worth of shares (571 units at $6.29), decreasing direct ownership by 6% to 9,713 units (SEC Form 4)

      4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)

      3/6/25 4:15:12 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, General Counsel&Secretary Mano Michael sold $17,568 worth of shares (2,793 units at $6.29), decreasing direct ownership by 12% to 21,047 units (SEC Form 4)

      4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)

      3/6/25 4:13:53 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP & Chief Commercial Officer Cheng Sohanya Roshan was granted 9,999 shares, increasing direct ownership by 36% to 37,759 units (SEC Form 4)

      4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)

      3/4/25 4:54:42 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Karyopharm Therapeutics Inc.

      SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)

      11/14/24 4:22:08 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Karyopharm Therapeutics Inc.

      SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)

      11/12/24 3:50:51 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Karyopharm Therapeutics Inc.

      SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)

      11/4/24 11:49:19 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Karyopharm Therapeutics Inc.

      SC 13G - Karyopharm Therapeutics Inc. (0001503802) (Subject)

      10/25/24 9:30:05 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Karyopharm Therapeutics Inc.

      SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)

      7/8/24 4:32:39 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Karyopharm Therapeutics Inc.

      SC 13G - Karyopharm Therapeutics Inc. (0001503802) (Subject)

      5/23/24 4:30:16 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Karyopharm Therapeutics Inc. (Amendment)

      SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)

      2/14/24 4:52:12 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Karyopharm Therapeutics Inc. (Amendment)

      SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)

      2/14/24 10:33:44 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Karyopharm Therapeutics Inc.

      SC 13G - Karyopharm Therapeutics Inc. (0001503802) (Subject)

      2/13/24 5:07:58 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Karyopharm Therapeutics Inc. (Amendment)

      SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)

      2/12/24 6:06:37 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Karyopharm Therapeutics Inc. Financials

    Live finance-specific insights

    See more
    • Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

      -- Conference Call Scheduled for Monday, May 12, 2025, at 4:30 p.m. ET -- NEWTON, Mass., May 8, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report first quarter 2025 financial results on Monday, May 12, 2025. Karyopharm's management team will host a conference call and audio webcast at 4:30 p.m. ET on Monday, May 12, 2025, to discuss the financial results and other company updates. To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeu

      5/8/25 4:05:00 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress

      – Total Revenue of $145 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $113 Million for Full Year 2024 – – Top-Line Data Readout from Phase 3 SENTRY Trial Evaluating Selinexor in Combination with Ruxolitinib in Patients with JAKi-Naïve Myelofibrosis Anticipated in 2H 2025; Company on Track to Complete Enrollment in 1H 2025 – – Company Announces Update to Phase 3 XPORT-EC-042 Trial of Selinexor as Maintenance Therapy in Advanced or Recurrent TP53 Wild-Type Endometrial Cancer. Following Dialogue with the FDA Regarding the Evolving Treatment Landscape, Trial to Focus Enrollment on Patients with Either pMMR Tumors or Patients with dMMR Tumors that are Medically Ineligible for Checkp

      2/19/25 7:30:00 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

      -- Conference Call Scheduled for Wednesday, February 19, 2025, at 8:00 a.m. ET -- NEWTON, Mass., Feb. 12, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report fourth quarter and full year 2024 financial results on Wednesday, February 19, 2025. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Wednesday, February 19, 2025, to discuss the financial results and other company updates. To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask

      2/12/25 7:00:00 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress

      – Achieves Third Quarter 2024 Total Revenue of $38.8 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $29.5 Million; Continued Regulatory and Reimbursement Approvals Globally – – Following FDA Alignment, Absolute Change in Total Symptom Score (Abs-TSS) Will Replace TSS50 as a Co-Primary Endpoint in Phase 3 SENTRY Trial in JAKi Naïve Myelofibrosis (MF); Expected Top-line Data Read-out Remains on Track for 2H 2025 – – Narrows Full-Year 2024 Total Revenue Guidance Range to $145.0 Million to $155.0 Million; U.S. XPOVIO Net Product Revenue Guidance Range to $110.0 Million to $115.0 Million; R&D and SG&A Expense Guidance Range to $255.0 Million to $265.0 Million – NEWTON, Mass., Nov. 5,

      11/5/24 7:30:00 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024

      -- Conference Call Scheduled for Tuesday, November 5, 2024, at 8:00 a.m. ET -- NEWTON, Mass., Oct. 31, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report third quarter 2024 financial results on Tuesday, November 5, 2024. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Tuesday, November 5, 2024, to discuss the financial results and other company updates. To access the conference call, please dial (800) 836-8184 (

      10/31/24 8:00:00 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis

      Co-primary Endpoint Changed to Absolute Total Symptom Score (Abs-TSS) from Total Symptom Score Improvement of ≥ 50% (TSS50) Following Alignment with the FDA Spleen Volume Response Rate ≥ 35% (SVR35) Remains a Co-primary Endpoint Promising Improvement in Abs-TSS and SVR35 from Phase 1 Trial of Selinexor in Combination with Ruxolitinib Adds Confidence in Phase 3 SENTRY Trial Proactively Increasing Total Sample Size of the SENTRY Trial to Approximately 350 Patients to Further Increase the Statistical Powering; Expected Top-line Data Read-out Remains in 2H 2025 Company to Host a Conference Call Today at 8:00 a.m. ET Featuring Drs. Raajit Rampal and John Mascarenhas NEWTON, Mass., Oct. 31, 2024

      10/31/24 7:30:00 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024

      Company to host a conference call tomorrow at 8:00 a.m. ET NEWTON, Mass., Oct. 30, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will host a conference call and audio webcast at 8:00 a.m. ET on Thursday, October 31, 2024 to provide a favorable study design update on the Company's pivotal Phase 3 SENTRY study in JAKi naive myelofibrosis. The call will feature leading myelofibrosis key opinion leaders Dr. Raajit Rampal, Director of the Center for Hematologic Maligna

      10/30/24 4:30:00 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

      – Achieves Second Quarter 2024 Total Revenue of $42.8 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $28.0 Million; Positive Momentum ex-US with Continued Regulatory and Reimbursement Approvals – – Updated Clinical Results at ASCO Annual Meeting Showed Median Progression-Free Survival (PFS) of 28.4 Months in the TP53 Wild-Type Exploratory Subgroup and 39.5 Months in the Proficient Mismatched Repair Status (pMMR) TP53 Wild-Type Exploratory Subgroup from Phase 3 SIENDO Study of Selinexor Maintenance Treatment in Advanced/Recurrent Endometrial Cancer – – Pre-Clinical Data Presented at the June 2024 European Hematology Association Meeting Support Selinexor's Mechanism of Action Targ

      8/6/24 7:30:00 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024

      -- Conference Call Scheduled for Tuesday, August 6, 2024, at 8:00 a.m. ET -- NEWTON, Mass., July 31, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report second quarter 2024 financial results on Tuesday, August 6, 2024. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Tuesday, August 6, 2024, to discuss the financial results and other company updates. To access the conference call, please dial (800) 836-8184 (local

      7/31/24 4:05:00 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

      – Announces Significant Refinancing Transactions and Amends Royalty Agreement with HealthCare Royalty Extending Vast Majority of Its Debt Maturities into 2028 and 2029, Well Beyond Expected Data Readouts and Potential Approvals from the Company's Three Phase 3 Trials, Strengthening the Company for its Next Stage of Growth –  – Achieves First Quarter 2024 Total Revenue of $33.1 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $26.0 Million – –  Reaffirms Full Year 2024 Total Revenue Guidance of $140.0 Million to $160.0 Million, Including U.S. XPOVIO Net Product Revenue Guidance of $100.0 Million to $120.0 Million – –        Invited to Present Updated Data from a Pre-Specified Explo

      5/8/24 7:30:00 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Karyopharm Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer

      NEWTON, Mass., Jan. 2, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Lori Macomber as Executive Vice President, Chief Financial Officer and Treasurer, effective January 3, 2025. In this role, Ms. Macomber will be responsible for leading and directing the financial activities of the Company. "Lori is an outstanding addition to the Karyopharm team," said Richard Paulson, President and Chief Executive Officer of Karyopharm. "She brings extensive experience in strategic financial management and operations, which will be critical as we execute on our strategy to grow

      1/2/25 7:00:00 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications

      NEWTON, Mass., Dec. 9, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications. "We are thrilled to have Brendan on board as we work towards delivering on and communicating important milestones for our organization in 2025," said Richard Paulson, President and Chief Executive Officer of Karyopharm. "Brendan's experience as a former sell-side analyst, advisor to biopharmaceutical companies and proven ability to develop strong investor relations and corporate communications programs wi

      12/9/24 8:00:00 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer

      NEWTON, Mass., Nov. 20, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Kristin Abate, the Company's Vice President, Accounting, Corporate Controller and Assistant Treasurer has been appointed the Company's Vice President, Chief Accounting Officer, and Assistant Treasurer, effective November 20, 2024. Ms. Abate, who has also served as the Company's interim principal financial officer and interim principal accounting officer since November 6, 2024, has been designated as the Company's principal accounting officer, effective November 20, 2024. Ms. Abate will continue to serve as t

      11/20/24 4:05:00 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Appoints Zhen Su, MD, MBA to its Board of Directors

      NEWTON, Mass., Sept. 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Zhen Su, MD, MBA, to its Board of Directors, effective August 31, 2023. Dr. Su is currently Chief Executive Officer and a member of the Board of Directors at Marengo Therapeutics, Inc., a company pioneering novel T-cell targeting therapeutics to fight cancer. "Dr. Su is a physician‐scientist and pharmaceutical industry leader who brings tremendous experience guiding products thro

      9/1/23 8:00:00 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DiaMedica Therapeutics Announces the Appointment of Biopharma Veteran Tanya Lewis to Its Board of Directors

      DiaMedica Continues Building Out Board Of Directors With Key Biopharma Industry Leaders DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment of Tanya Lewis to its board of directors effective March 1, 2023. Ms. Lewis, a recognized leader in the biopharma industry, brings over 25 years of experience in drug development, having played a key role in the approval of multiple new drugs. Ms. Lewis currently serves as the Chief Development Operations Officer at Replimune Group, Inc. where she has oversight for development of an integrated clinica

      3/6/23 8:30:00 AM ET
      $DMAC
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Announces Further Transition of Co-Founders Sharon Shacham PhD, MBA and Michael Kauffman, MD, PhD and appointment of Reshma Rangwala, MD, PhD as Chief Medical Officer

      - Formerly of Aravive, Genmab and Merck & Co., Dr. Rangwala will Lead Karyopharm's Clinical Development Programs and Strategy - - As Part of Karyopharm's Evolution, Co-Founders Dr. Shacham and Dr. Kauffman Will Transition Out of the Company on May 31, 2022 -  - Dr. Shacham Will Continue her Engagement with the Company's Scientific Advisory Board and Serve in an Advisory Capacity - NEWTON, Mass., March 29, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Reshma Rangwala, MD, PhD, as the Company's Chief Medical Officer. Dr. Rangwala will join the Company in mid-April

      3/29/22 8:00:00 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Names New Head of Investor Relations

      – Elhan Webb, CFA, Formerly of Rubius Therapeutics and Radius Health, Appointed as Senior Vice President of Investor Relations – – Webb Brings More than 20 Years of Diverse International Experience Across Investor Relations, Business Development, Investment Analysis and Portfolio Management in the Healthcare and Biotechnology Fields – NEWTON, Mass., March 14, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Elhan Webb as Senior Vice President of Investor Relations.   "Elhan brings tremendous experience with sell-side and buy-side analysts, as well as a robust networ

      3/14/22 7:00:00 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Announces Changes to Its Clinical Leadership Team

      NEWTON, Mass., Feb. 22, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced changes to its clinical leadership team, including the appointment of Patricia Judson, M.D., as Senior Vice President of Medical Strategy and Stuart Poulton as Senior Vice President of Strategy and Portfolio Management. In addition, Jatin Shah, M.D. Executive Vice President and Chief Medical Officer has stepped down to pursue other professional opportunities, but will continue to serve Karyopharm in an advisory capacity. "As accomplished leaders with proven track records, Patricia and Stuart's expertise will be i

      2/22/22 7:00:00 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Announces the Appointment of Peter K Honig, MD, MPH to its Board of Directors

      NEWTON, Mass., Dec. 6, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Peter K Honig, MD, MPH, to the Board of Directors, effective December 3, 2021. Dr. Honig brings to Karyopharm over 30 years of drug development and regulatory sciences experience from past leadership roles with Pfizer, Merck and the U.S. Food and Drug Administration (FDA). Dr. Honig replaces Mikael Dolsten, MD, PhD, who has transitioned off the Board due to competing professional demands, effective December 2, 2021. "We are honored to welcome Dr. Honig to our Board of Directors. His deep knowle

      12/6/21 4:05:00 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress

      NEWTON, Mass., May 3, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended March 31, 2021. In addition, Karyopharm highlighted select corporate milestones, including details regarding the appointment of its next President and Chief Executive Officer, the ongoing U.S. commercialization of XPOVIO, and regulatory progress in Europe, and provided an overview of its key clinical development programs. "We are encouraged to see patient demand for XPOVIO return to growth in the first quarter of 2021, and we remain confident in its long-term commercial potent

      5/3/21 7:05:00 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Karyopharm Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler initiated coverage on Karyopharm Therapeutics with a new price target

      Piper Sandler initiated coverage of Karyopharm Therapeutics with a rating of Overweight and set a new price target of $8.00

      1/19/23 7:43:39 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Therapeutics upgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts upgraded Karyopharm Therapeutics from Sector Perform to Outperform and set a new price target of $10.00 from $7.00 previously

      11/4/22 7:23:40 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital reiterated coverage on Karyopharm Therapeutics with a new price target

      RBC Capital reiterated coverage of Karyopharm Therapeutics with a rating of Sector Perform and set a new price target of $8.00 from $12.00 previously

      3/8/22 7:29:51 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Karyopharm Therapeutics with a new price target

      SVB Leerink reiterated coverage of Karyopharm Therapeutics with a rating of Market Perform and set a new price target of $6.00 from $8.00 previously

      3/2/22 4:30:26 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Therapeutics upgraded by JP Morgan with a new price target

      JP Morgan upgraded Karyopharm Therapeutics from Underweight to Neutral and set a new price target of $8.00

      2/9/22 5:02:48 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Karyopharm Therapeutics with a new price target

      SVB Leerink reiterated coverage of Karyopharm Therapeutics with a rating of Market Perform and set a new price target of $8.00 from $6.00 previously

      1/10/22 11:13:46 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital reiterated coverage on Karyopharm Therapeutics with a new price target

      RBC Capital reiterated coverage of Karyopharm Therapeutics with a rating of Sector Perform and set a new price target of $9.00 from $8.00 previously

      12/9/21 6:52:31 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Therapeutics downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Karyopharm Therapeutics from Overweight to Equal-Weight and set a new price target of $10.00 from $27.00 previously

      11/19/21 7:16:37 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley reiterated coverage on Karyopharm Therapeutics with a new price target

      Morgan Stanley reiterated coverage of Karyopharm Therapeutics with a rating of Overweight and set a new price target of $27.00 from $29.00 previously

      10/12/21 8:28:27 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Therapeutics downgraded by JP Morgan

      JP Morgan downgraded Karyopharm Therapeutics from Overweight to Neutral

      8/6/21 7:17:22 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care